Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 51(4): 1007-25, 2008 Feb 28.
Article in English | MEDLINE | ID: mdl-18232657

ABSTRACT

Platelet P2Y12 receptors play a central role in the regulation of platelet function and inhibition of this receptor by treatment with drugs such as clopidogrel results in a reduction of atherothrombotic events. We discovered that modification of natural and synthetic dinucleoside polyphosphates and nucleotides with lipophilic substituents on the ribose and base conferred P2Y12 receptor antagonist properties to these molecules producing potent inhibitors of ADP-mediated platelet aggregation. We describe methods for the preparation of these functionalized dinucleoside polyphosphates and nucleotides and report their associated activities. By analysis of these results and by deconstruction of the necessary structural elements through selected syntheses, we prepared a series of highly functionalized nucleotides, resulting in the selection of an adenosine monophosphate derivative (62) for further clinical development.


Subject(s)
Blood Platelets/metabolism , Membrane Proteins/antagonists & inhibitors , Nucleotides/chemical synthesis , Platelet Aggregation Inhibitors/chemical synthesis , Purinergic P2 Receptor Antagonists , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/chemical synthesis , Adenosine Monophosphate/chemistry , Adenosine Monophosphate/pharmacology , Calcium/metabolism , Cell Line, Tumor , Dinucleoside Phosphates/chemical synthesis , Dinucleoside Phosphates/chemistry , Dinucleoside Phosphates/pharmacology , Humans , In Vitro Techniques , Nucleotides/chemistry , Nucleotides/pharmacology , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/chemistry , Platelet Aggregation Inhibitors/pharmacology , Receptors, Purinergic P2Y12 , Structure-Activity Relationship
2.
Purinergic Signal ; 1(2): 183-91, 2005 Jun.
Article in English | MEDLINE | ID: mdl-18404503

ABSTRACT

Dinucleoside polyphosphates act as agonists on purinergic P2Y receptors to mediate a variety of cellular processes. Symmetrical, naturally occurring purine dinucleotides are found in most living cells and their actions are generally known. Unsymmetrical purine dinucleotides and all pyrimidine containing dinucleotides, however, are not as common and therefore their actions are not well understood. To carry out a thorough examination of the activities and specificities of these dinucleotides, a robust method of synthesis was developed to allow manipulation of either nucleoside of the dinucleotide as well as the phosphate chain lengths. Adenosine containing dinucleotides exhibit some level of activity on P2Y(1) while uridine containing dinucleotides have some level of agonist response on P2Y(2) and P2Y(6). The length of the linking phosphate chain determines a different specificity; diphosphates are most accurately mimicked by dinucleoside triphosphates and triphosphates most resemble dinucleoside tetraphosphates. The pharmacological activities and relative metabolic stabilities of these dinucleotides are reported with their potential therapeutic applications being discussed.

3.
J Pharmacol Exp Ther ; 311(3): 1038-43, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15345752

ABSTRACT

ADP is the cognate agonist of the P2Y1, P2Y12, and P2Y13 receptors. With the goal of identifying a high potency agonist that selectively activates the P2Y1 receptor, we examined the pharmacological selectivity of the conformationally constrained non-nucleotide analog (N)-methanocarba-2MeSADP [(1'S,2'R, 3'S,4'R,5'S)-4-[(6-amino-2-methylthio-9H-purin-9-yl)-1-diphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol] among the three ADP-activated receptors. Each P2Y receptor was expressed transiently in COS-7 cells, and inositol lipid hydrolysis was quantified as a measure of receptor activity. In the case of the Gi-linked P2Y12 and P2Y13 receptors, a chimeric G protein, Galphaq/i, was coexpressed to confer a capacity of these Gi-linked receptors to activate phospholipase C. 2MeSADP (2-methylthio-ADP) was a potent agonist at all three receptors exhibiting EC50 values in the sub to low nanomolar range. In contrast, whereas (N)-methanocarba-2MeSADP was an extremely potent (EC50=1.2 +/- 0.2 nM) agonist at the P2Y1 receptor, this non-nucleotide analog exhibited no agonist activity at the P2Y12 receptor and very low activity at the P2Y13 receptor. (N)-Methanocarba-2MeSADP also failed to block the action of 2MeSADP at the P2Y12 and P2Y13 receptors, indicating that the (N)-methanocarba analog is not an antagonist at these receptors. The P2Y1 receptor selectivity of (N)-methanocarba-2MeSADP was confirmed in human platelets where it induced the shape change promoted by P2Y1 receptor activation without inducing the sustained platelet aggregation that requires simultaneous activation of the P2Y12 receptor. These results provide the first demonstration of a high-affinity agonist that discriminates among the three ADP-activated P2Y receptors, and therefore, introduce a potentially important new pharmacological tool for delineation of the relative biological action of these three signaling proteins.


Subject(s)
Adenosine Diphosphate/analogs & derivatives , Adenosine Diphosphate/pharmacology , Membrane Proteins/agonists , Purinergic P2 Receptor Agonists , Adenosine Diphosphate/chemistry , Animals , Blood Platelets/drug effects , Blood Platelets/metabolism , COS Cells , Chlorocebus aethiops , Drug Design , Humans , In Vitro Techniques , Membrane Proteins/antagonists & inhibitors , Membrane Proteins/genetics , Molecular Conformation , Purinergic P2 Receptor Antagonists , Receptors, G-Protein-Coupled/drug effects , Receptors, Purinergic P2/genetics , Receptors, Purinergic P2Y1 , Receptors, Purinergic P2Y12 , Structure-Activity Relationship , Transfection , Type C Phospholipases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...